178160-22-0

Basic information

• Product Name: ETHYL 5-NITRO-3-OXO-2,3-DIHYDRO-1H-INDAZOLE-1-CARBOXYLATE
• Synonyms: ETHYL 5-NITRO-3-OXO-2,3-DIHYDRO-1H-INDAZOLE-1-CARBOXYLATE;3-Hydroxy-5-nitro-indazole-1-carboxylic acid ethyl ester
• CAS NO: 178160-22-0
• Molecular Formula: C₁₀H₉N₃O₅
• Molecular Weight: 251.2
• Mol File: 178160-22-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 5-NITRO-3-OXO-2,3-DIHYDRO-1H-INDAZOLE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-NITRO-3-OXO-2,3-DIHYDRO-1H-INDAZOLE-1-CARBOXYLATE(178160-22-0)
• EPA Substance Registry System: ETHYL 5-NITRO-3-OXO-2,3-DIHYDRO-1H-INDAZOLE-1-CARBOXYLATE(178160-22-0)

Safety Data

• Hazardous Substances Data: 178160-22-0(Hazardous Substances Data)

Upstream product

• 6942-36-5 methyl 2-bromo-5-nitrobenzoate 
• 541-41-3 chloroformic acid ethyl ester 
• 61346-19-8 5-nitroindazolin-3-one 
• 6307-82-0 2-chloro-5-nitro-benzoic acid methyl ester 

Downstream Products

• 178160-25-3 2-Benzyl-5-nitro-1,2-dihydro-3H-indazol-3-one 
• 1210312-43-8 C₁₇H₁₇N₃O₃ 
• 1416330-19-2 C₁₇H₁₇N₃O₃ 
• 1210312-50-7 C₁₇H₁₇N₃O₃ 
• 1210312-32-5 VATR-1 
• 1210312-38-1 C₁₁H₁₃N₃O₃ 
• 1416330-30-7 C₁₁H₁₃N₃O₃ 
• 1210312-52-9 C₁₁H₁₃N₃O₃ 
• 1210312-37-0 C₁₁H₁₃N₃O₃ 
• 1210312-45-0 C₂₁H₁₇N₃O₃ 
• 1210312-48-3 C₁₉H₂₁N₃O₃ 
• 1352138-00-1 VATR-4 
• 1391707-83-7 2-benzyl-1-butyl-5-nitroindazolin-3-one 
• 1416330-25-0 C₁₈H₁₉N₃O₃ 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

New cannabinoid receptor antagonists as pharmacological tool

Synthesis and pharmacological evaluation of a new series of cannabinoid receptor antagonists of indazole ether derivatives have been performed. Pharmacological evaluation includes radioligand binding assays with [3H]-CP55940 for CB1 and CB2 receptors and functional activity for cannabinoid receptors on isolated tissue. In addition, functional activity of the two synthetic cannabinoids antagonists 18 (PGN36) and 17 (PGN38) were carried out in the osteoblastic cell line MC3T3-E1 that is able to express CB2R upon osteogenic conditions. Both antagonists abolished the increase in collagen type I gene expression by the well-known inducer of bone activity, the HU308 agonist. The results of pharmacological tests have revealed that four of these derivatives behave as CB2R cannabinoid antagonists. In particular, the compounds 17 (PGN38) and 18 (PGN36) highlight as promising candidates as pharmacological tools.

PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS

Compounds of formula (I): wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS

Compounds of formula (I) wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

Designing drugs with a specific multi-target profile is a promising approach against multifactorial illnesses as Alzheimer's disease. In this work, new indazole ethers that possess dual activity as both cannabinoid agonists CB2 and inhibitors of BuChE have been designed by computational methods. On the basis of this knowledge, the synthesis, pharmacological evaluation and docking studies of a new class of indazoles has been performed. Pharmacological evaluation includes radioligand binding assays with [3H]-CP55940 for CB1R and CB2R and functional activity for cannabinoid receptors on isolated tissue. Additionally, in vitro inhibitory assays of AChE/BuChE and the corresponding competition studies have been carried out. The results of pharmacological tests have revealed that three of these derivatives behave as CB2 cannabinoid agonists and simultaneously show BuChE inhibition. In particular, compounds 3 and 24 have emerged as promising candidates as novel cannabinoids that inhibit BuChE by a non-competitive or mixed mechanism, respectively. On the other hand, both molecules show antioxidant properties.

New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and mechanism of action studies

New 5-nitroindazole derivatives were developed and their antichagasic properties studied. Eight compounds (14-18, 20, 26 and 28) displayed remarkable in vitro activities against Trypanosoma cruzi (T. cruzi). Its unspecific cytotoxicity against macrophages

Analogues of cytostatic, fused indazolinones: Synthesis, conformational analysis and cytostatic activity against HeLa cells of some 1-substituted indazolols, 2-substituted indazolinones, and related compounds

A number of indazol-3-ol and indazolin-3-one derivatives were designed as open-chain analogues of some previously studied cytostatic tetranuclear indazolinones. The former were prepared by starting with alkylation of the parent indazolinones (11 or its 5-